Pe, an international, eventdriven, openlabel, assessorblind, noninferiority study. The einstein pe study was a randomized, openlabel trial of the efficacy and safety of rivaroxaban as compared with standard therapy consisting of enoxaparin and a vitamin k antagonist in. Jan 17, 2015 the global einstein dvt and pe studies compared rivaroxaban 15 mg twice daily for 3 weeks followed by 20 mg once daily with enoxaparinvitamin k antagonist therapy and demonstrated noninferiority for efficacy and superiority for major bleeding. The approval of rivaroxaban for the treatment of deep vein thrombosis and pulmonary embolism and the extended secondary prevention of recurrent vte is based on the results of the einstein dvt and einstein pe trials, and the einstein ext and einstein choice trials. Applications that remain active, even if the product has been discontinued, undergo safetyrelated labeling changes. A prespecified pooled analysis of the einstein dvt and einstein pe studies compared the efficacy and safety of rivaroxaban 15 mg twicedaily for 21 days, followed by 20 mg oncedaily with standardtherapy enoxaparin 1. Mar 24, 2019 einsteinpe investigators, buller hr, prins mh, lensin aw.
Rivaroxaban revolutionises treatment of pulmonary embolism. Rivaroxaban will be administered in a body weightadjusted 20 mgequivalent total daily dose regimen using immediate release filmcoated tablets with a dosage of 5, 10, 15, or 20 mg, or an oral suspension 1 mgml. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism. The international multicenter study enrolled 3,396 patients average age 59 years, 45 percent women, 77 percent white. Einstein dvt and einstein pe were randomized, openlabel studies that compared the efficacy and safety of rivaroxaban with standard therapy, consisting of enoxaparin and adjusteddose vka, in patients with acute, symptomatic dvt andor pe. I developed a pulmonary embolism following a partial hysterectomy. The einstein pe study was an openlabel, randomized, phase iii study trial registration number nct00439777 comparing oral rivaroxaban 15 mg twice daily for 3 weeks, followed by 20 mg once daily thereafter with subcutaneous enoxaparin overlapping with and followed by a vka warfarin or acenocoumarol.
Rivaroxaban for the treatment of symptomatic deepvein. The einsteinpe study was a randomized, openlabel trial of the efficacy and safety of rivaroxaban as compared with standard therapy consisting of enoxaparin and a vitamin k antagonist in. Idarucizumab for dabigatran reversal, rivaroxaban for. In the einstein dvt and einstein pe trials, rivaroxaban 15 mg twice. In the einstein dvt and einstein pe trials, rivaroxaban 15 mg twice daily for 21 days, followed by 20 mg once daily thereafter was shown to be an effective and safe alternative to standard. Rivaroxaban for the treatment of deep vein thrombosis or pulmonary embolism. Owing to the different anticoagulant regimens used in japan, japanese patients were not enrolled into the global einstein dvt and pe trials. Among patients in the einstein choice trial who had completed a 6 to 12month course of anticoagulation for vte, extending anticoagulation with either prophylaxis 10 mg or treatment 20 mg doses of rivaroxaban for 1 year is superior to aspirin in reducing recurrent vte events. Pdf rivaroxaban for the treatment of symptomatic deepvein.
Treatment of venous thromboembolism open access journals. Pdf the worldwide einstein dvt and einstein pe studies randomized 8282 patients with acute symptomatic. Rivaroxaban for the treatment of venous thromboembolism in r. The einstein jr phase iii study 39 is a randomized, openlabel, study comparing the efficacy and safety of rivaroxaban 20mgequivalent dose regimens with those of standard anticoagulation for. Rivaroxaban and the einstein clinical trial programme ncbi. Oral rivaroxaban for pulmonary embolism article pdf available in new england journal of medicine 36626. Rivaroxaban for treating pulmonary embolism and preventing. The einstein dvt study investigated rivaroxaban compared with initial.
In this large, international, phase iii clinical program in more than 8000 patients with acute symptomatic dvt andor pe, monotherapy with rivaroxaban was shown to be as effective as dualdrug therapy with enoxaparin overlapping with and followed by vka. Sep 05, 2019 einsteinpe investigators, buller hr, prins mh, lensin aw. The treatment regimens that we confirmed in children with bodyweights of at least 20 kg and the revised treatment regimens that we predicted in those with bodyweights less than 20 kg will be evaluated in the einstein jr phase 3 trial in children with acute venous thromboembolism. The einstein pe study was been heralded as a landmark study in the field of pulmonary embolism and marks a turning point in its management. Patientreported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of pulmonary embolism. As a 35yearold mom with young children, i appreciated the convenience, since it doesnt require injections or weekly blood tests. Rivaroxaban is recommended as an option for treating pulmonary embolism and preventing recurrent deep vein thrombosis and pulmonary embolism in adults. Recurrence of pulmonary embolism while on rivaroxaban. Jun 30, 2019 oral rivaroxaban for the treatment of symptomatic pulmonary embolism. Rivaroxaban for the treatment of symptomatic deepvein thrombosis and pulmonary embolism in chinese patients. This is a multicenter, randomized, openlabel, assessorblind, eventdriven, noninferiority program for efficacy with a study treatment duration of 3, 6 or 12 months in patients with confirmed acute symptomatic pulmonary embolism pe with or without symptomatic deepvein thrombosis dvt einstein pe. A prespecified pooled analysis of the einsteindvt and einsteinpe studies compared the efficacy and safety of rivaroxaban 15 mg.
Pharmacodynamic and pharmacokinetic basics of rivaroxaban. In the einstein dvt and einstein pe trials, rivaroxaban 15 mg twice daily for 21 days. Rivaroxaban, a direct oral anticoagulant, is widely used for the treatment of venous thromboembolism vte in adult patients. Dec 16, 20 the einstein dvt and einstein pe studies evaluated rivaroxaban for the treatment of vte. The einstein pe 32 study involved patients with acute symptomatic pe with or without dvt. Rivaroxaban and usual care had similar rates of recurrent. The new oral factor xa inhibitor rivaroxaban proved equivalent to standard care of lmwh plus vitamink antagonist for the treatment of acute pulmonary embolism in the einstein. The primary efficacy outcome occurred in 17 of 1107 patients 1. Oral direct factor xa inhibitor rivaroxaban in patients with. In a randomized, openlabel, eventdriven, noninferiority trial involving 4832 patients who had acute symptomatic pulmonary embolism with or without deepvein thrombosis, we compared rivaroxaban. Rivaroxaban was noninferior to standard therapy in preventing recurrent venous thromboembolism postpe hr 1. In the einstein jr phase 1 and 2 studies, bodyweightadjusted rivaroxaban dose regimens with tablets or a newly developed oral suspension have been established for children aged between birth and 18 years matching the exposure range of young adults treated with rivaroxaban 20 mg once daily.
Oral, direct factor xa inhibitor rivaroxaban in patients with acute symptomatic deep vein thrombosis or pulmonary embolism. Oral rivaroxaban versus standard therapy for the treatment of. Background rivaroxaban, an oral factor xa inhibitor, may provide a simple, fixed dose regimen for treating acute. Rivaroxaban, a direct oral anticoagulant, is widely used for the treatment of venous thromboembolism. In the 2 pivotal clinical trials, where oral rivaroxaban was evaluated for the treatment of vte einstein and einsteinpe trials, 9,10 the results were consistent with all doac trials for the vte treatment when compared to heparin followed by vkasame efficacy profile with significantly lower bleeding rates was observed in noncancer patients. Oral rivaroxaban for symptomatic venous thromboembolism nejm. The oral administration of rivaroxaban 15 mg twice a day for the first 3 weeks, followed by 20 mg. Rivaroxaban is a direct factor xa inhibitor used for treatment and prevention of venous thromboembolism vte. Einsteinpulmonary embolism pe study american college of. Rivaroxaban inhibits factorxa in the coagulation cascade. Oral, direct factor xa inhibitor rivaroxaban in patients with acute symptomatic deep vein thrombosis or. Longterm anticoagulation with rivaroxaban for preventing. Oral rivaroxaban for japanese patients with symptomatic.
Rivaroxaban andor its metabolites were present in the milk of rats. Oral direct factor xa inhibitor rivaroxaban in patients. Patients were eligible if they were of legal age and had objectively confirmed acute, symptomatic dvt andor pe. As in einstein dvt, treatment satisfaction was a predefined outcome in the einstein pe study, and here we compare the burdens and benefits of rivaroxaban as an oral fixeddose regimen, versus dualdrug standard of care in patients with pe enrolled in the einstein pe study. Einsteinpe investigators, buller hr, prins mh, lensin aw.
Jun 06, 2019 in the einstein dvt and einstein pe studies, xarelto was demonstrated to be noninferior to enoxaparinvka for the primary composite endpoint of time to first occurrence of recurrent dvt or nonfatal or fatal pe einstein dvt hr 95% ci. Indeed, the einstein pe showed that a singledrug regimen of rivaroxaban start. In the einstein dvt and einstein pe studies, xarelto was demonstrated to be noninferior to enoxaparinvka for the primary composite endpoint of time to first occurrence of recurrent dvt or nonfatal or fatal pe einstein dvt hr 95% ci. Rivaroxaban or aspirin for extended treatment of venous. Each study was eventdriven and required a number of events to provide 90% power using a margin of 2. In the einstein dvt and einstein pe trials, rivaroxaban 15 mg.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Randomized, phase 3, multicenter, openlabel, parallelgroup, activecontrolled, eventdriven, noninferiority studies einstein dvt and einstein pe with patients receiving xarelto at an initial dose of 15 mg twice daily with food for the first 3 weeks, followed by xarelto 20 mg once daily with food or enoxaparin 1 mgkg twice daily for at least 5 days. Pdf rivaroxaban versus standard anticoagulation for. Have the einstein pe investigators reported what is probably the next important advance in the treatment of pe. Rivaroxaban was noninferior to standard therapy in preventing recurrent venous thromboembolism post pe hr 1. Rivaroxaban will reduce symptomatic recurrent venous thromboembolism. Rivaroxaban and the einstein clinical trial programme. Oral rivaroxaban for symptomatic venous thromboembolism. Patientreported treatment satisfaction with oral rivaroxaban. Apr 14, 2019 oral rivaroxaban for the treatment of symptomatic pulmonary embolism. Einstein jr is the largest pediatric study ever conducted for the treatment of vte and shows that the efficacy and safety profile of rivaroxaban. The einstein pe study was designed to compare efficacy and safety of fixeddose oral rivaroxaban therapy against standard heparin plus warfarin in the treatment of symptomatic pulmonary emboli. Rivaroxaban versus standard anticoagulation for acute.
The results show that replacing the effective, but cumbersome, combination of injectable and oral agents at initiation of anticoagulation with a single oral anticoagulant rivaroxaban, which does not need routine monitoringproduced efficacy and safety outcomes that were similar. Pdf rivaroxaban and the einstein clinical trial programme. Can i use rivaroxaban to treat a pulmonary embolism pe in a patient with active cancer. This was a predefined safety analysis of the einstein pe study, including pe patients, randomized to either enoxaparin with vitamin k antagonist vka or rivaroxaban. Published in, einsteinpe randomized 4, patients with acute pe to rivaroxaban or standard therapy with enoxaparin and a vka. It is the largestever study of pe, recruiting and was significant 4 833 patients from 36 countries, including south africa. Einstein extension trial, which compared continued rivaroxaban with placebo in 1,197 patients with symptomatic dvt or pe who had completed 6 to 12 months of anti coagulation and in whom physicians had equipoise with respect to the need for continued. Rivaroxaban compared with standard anticoagulants for the. Oral rivaroxaban for the treatment of symptomatic venous. Einstein pe investigators, buller hr, prins mh, lensin aw. Funded by bayer healthcare and janssen pharmaceuticals. We conducted the japanese j einstein dvt and pe program to compare rivaroxaban with the japanese. Rivaroxaban is a new oral anticoagulant indicated for the treatment of venous thromboembolic events vte including deep vein thrombosis dvt and pulmonary embolism pe. Pdf rivaroxaban for the treatment of pulmonary embolism.
The einstein dvt and einstein pe studies were each designed to test the hypothesis that rivaroxaban would be noninferior to standardtherapy. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. Rivaroxaban for cancerassociated venous thromboembolism. A fixeddose regimen of rivaroxaban alone was noninferior to standard therapy for the initial and longterm treatment of pulmonary embolism and had a potentially improved benefitrisk profile. Rivaroxaban equals standard therapy, halves major bleeding. Aug 16, 2011 einstein dvt, einstein ext and einstein pe are phase iii studies designed to evaluate the efficacy and safety of rivaroxaban in the treatment andor prevention of recurrent, symptomatic vte in patients with acute symptomatic deep vein thrombosis or pulmonary embolism. Reduceddosed rivaroxaban in the longterm prevention of. Einstein choice is the first study to directly compare lowdose rivaroxaban and aspirin in this population in whom there is equipoise regarding the benefit of continued therapy.
Rivaroxaban for the treatment of deep vein thrombosis or. Oral direct factor xa inhibitor rivaroxaban in patients with acute symptomatic pulmonary embolism the einstein pe study. Two studies, einstein dvt and einstein pe, compared a singledrug approach using the oral, direct factor xa inhibitor rivaroxaban with standardtherapy consisting of enoxaparin overlapping with and followed by a vka for the treatment of dvt andor pe 8, 9. Anticoagulation using a fixeddose regimen of rivaroxaban has been shown to be as effective as standard anticoagulant therapy and is an attractive alternative due to its efficacy and lack of requirement of monitoring. Treatment with bodyweightadjusted rivaroxaban appears to be safe in children. The new oral factor xa inhibitor rivaroxaban proved equivalent to standard care of lmwh plus vitamink antagonist for the treatment of acute pulmonary embolism in the einstein pe study reported today.
The objective of einstein pe was to determine whether a singledrug approach with oral rivaroxaban is at least as effective as noninferior to dualdrug therapy with enoxaparinvka and to compare the safety of these two approaches in the treatment of patients with confirmed acute symptomatic pe with or without symptomatic dvt. Final appraisal determination rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism issue date. Owing to differences in targeted anticoagulant intensities in japan, japanese patients were not enrolled into the global studies. Bodyweightadjusted rivaroxaban for children with venous.
Idarucizumab for dabigatran reversal, rivaroxaban for pe. In the einstein pe study 3 of 4832 patients with acute symptomatic pulmonary embolism pe with or without deep vein thrombosis, it was demonstrated that rivaroxaban xarelto, bayer is at least as effective as the standard therapy of subcutaneous injections of the low molecular weight heparin lmwh enoxaparin and warfarin. Oral rivaroxaban for the treatment of symptomatic pulmonary. In chinese patients with acute symptomatic dvt andor pe, rivaroxaban was as efficacious as enoxaparin. Background rivaroxaban, an oral factor xa inhibitor, may provide a simple, fixeddose regimen for treating acute. Oral rivaroxaban versus standard therapy for the treatment. Rivaroxaban for the treatment of venous thromboembolism in. The rate of major bleeding was also lower in the rivaroxaban group, as compared to standard therapy hr 0. Randomized, openlabel phase iii noninferiority study active treatment. The einstendvt trial demonstrated that rivaroxaban is noninferior to standard therapy i.
584 1403 936 1131 192 267 16 1122 1316 514 590 751 149 1371 704 118 688 302 1617 351 125 958 106 62 256 1632 663 1202 243 1239 1425 1288 1039 1429 446 674 1354 418 636